Palisade Bio (NASDAQ:PALI) Gets FDA Response: Stock Ends Higher In Volatile Trade

March 23, 2022

Biotech firm Palisade Bio (NASDAQ:PALI) came into significant focus among investors on Tuesday and ended up with gains of as much as 30% amidst heavy interest. Considering the magnitude of the gains made by the stock, it may be a good time for investors to consider taking a look at the announcement that led to the rally. Trading Data On Tuesday, PALI stock surged 30.43% to $1.05 with more than…